Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.

Autor:	Enríquez-Rodríguez AI; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Hermida Valverde T; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Romero Álvarez P; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., López-González FJ; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Gullón Blanco JA; Department of Pulmonary Medicine, Hospital Universitario de San Agustín, Avilés, Spain., Expósito Villegas AR; Department of Pulmonary Medicine, Hospital Universitario de Cabueñes, Gijón, Spain., Escobar Fernández MJ; Department of Pulmonary Medicine, Hospital Universitario de Cabueñes, Gijón, Spain., Beristáin Urquiza AM; Department of Allergy Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Alonso Fernández MÁ; Department of Pulmonary Medicine, Hospital Vital Álvarez Buylla, Mieres, Spain., Gutiérrez Rodríguez M; Department of Pulmonary Medicine, del Hospital Carmen y Severo Ochoa, Cangas del Narcea, Spain., Castaño De Las Pozas G; Department of Pulmonary Medicine, Hospital Público Comarcal de Jarrio, Jarrio, Spain., Jiménez Pérez J; Department of Pulmonary Medicine, Hospital Francisco Grande Covián, Arriondas, Spain., Fernández Mellado R; Department of Pulmonary Medicine, Hospital Valle del Nalón, Langreo, Spain., García Clemente MM; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Casan Clara P; Department of Pulmonary Medicine, Hospital Universitario Central de Asturias-Universidad de Oviedo, ISPA-FINBA, Oviedo, Spain.
Jazyk:	angličtina
Zdroj:	The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2022 May; Vol. 59 (5), pp. 1005-1011. Date of Electronic Publication: 2021 Mar 27.
DOI:	10.1080/02770903.2021.1897835
Abstrakt:	Objective: Add-on therapy with monoclonal antibodies is the recommended therapy for severe asthmatic patients refractory to maintenance treatment. In randomized control trials, mepolizumab reduced the number of exacerbations, the need of oral corticosteroids (OCS), increased asthma control, and lung function in a population of uncontrolled severe eosinophilic asthmatic patients. In this piece of work, we aimed to assess mepolizumab efficacy and safety in a cohort of patients with severe eosinophilic asthma in real-life conditions. Methods: A retrospective study was carried out at eight hospitals from Asturias (Spain). The sample included patients treated with mepolizumab from 1 January 2016 to 31 March 2019. Demographic and clinical variables were collected, including OCS use, asthma control, lung function, and exacerbation rate. Results: Sixty-nine patients (72% women) with mean age 56 ± 13 years were included. Annual exacerbation rate decreased from 4.7 (SD 3.7) to 1.3 (SD 2.5) ( p  < 0.001). The number of patients requiring OCS treatment decreased from 25 patients (36%, mean prednisone dose = 18 mg/day) to 13 patients (19%, mean prednisone dose = 9 mg/day) ( p  < 0.001). Twelve patients (48%) stopped OCS treatment. Forced expired volume in one second (FEV1) as percentage increased from 68% (SD 20) to 76% (SD 21) ( p  < 0.001). Fifty-six patients (81%) were considered responders to mepolizumab. No serious adverse events were detected during the study period. Conclusions: Overall, this study demonstrates mepolizumab efficacy and safety in a cohort of patients with uncontrolled severe eosinophilic asthma in routine clinical practice.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu